Enovis (NYSE:ENOV) Shares Up 14.1% – Should You Buy?

Enovis Corporation (NYSE:ENOV) shares traded up 14.1% on Wednesday. The stock traded as high as $24.01 and last traded at $23.8440. Approximately 205,270 shares changed hands during trading, a decline of 83% from the average session volume of 1,233,179 shares. The stock had previously closed at $20.89.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ENOV shares. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Citizens Jmp dropped their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Needham & Company LLC reduced their price target on shares of Enovis from $52.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, BTIG Research cut their price objective on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, September 1st. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $37.25.

Enovis Price Performance

The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The firm has a 50-day moving average of $19.82 and a 200-day moving average of $23.05. The stock has a market cap of $1.41 billion, a PE ratio of -1.26 and a beta of 1.31.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. Enovis’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period last year, the firm posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts predict that Enovis Corporation will post 3.15 EPS for the current year.

Insider Activity at Enovis

In other news, CEO Damien Mcdonald acquired 13,035 shares of the business’s stock in a transaction on Friday, September 4th. The stock was bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Oliver Engert purchased 5,140 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was bought at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the purchase, the insider directly owned 61,238 shares in the company, valued at $1,191,691.48. This trade represents a 9.16% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 23,293 shares of company stock valued at $449,599 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Institutional Trading of Enovis

Several large investors have recently added to or reduced their stakes in ENOV. Private Management Group Inc. boosted its holdings in Enovis by 31.3% in the 3rd quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock valued at $32,748,000 after purchasing an additional 427,347 shares during the last quarter. Fulcrum Asset Management LLP raised its position in shares of Enovis by 2,739.4% during the 3rd quarter. Fulcrum Asset Management LLP now owns 20,330 shares of the company’s stock valued at $375,000 after buying an additional 19,614 shares during the period. Villanova Investment Management Co raised its position in shares of Enovis by 10.2% during the 3rd quarter. Villanova Investment Management Co now owns 148,424 shares of the company’s stock valued at $2,712,000 after buying an additional 13,740 shares during the period. Bfsg LLC lifted its holdings in Enovis by 24.6% in the third quarter. Bfsg LLC now owns 13,282 shares of the company’s stock valued at $243,000 after acquiring an additional 2,622 shares during the last quarter. Finally, MGO One Seven LLC purchased a new position in Enovis in the third quarter worth approximately $200,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.